|
|
Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Trial Contact Information Registry Information
Alternate Title
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase II | Treatment | Closed | 18 and over | GOG-0170D NCT00022659 |
Objectives - Determine the 6-month progression-free survival of patients with persistent or recurrent ovarian epithelial or primary peritoneal cancer treated with bevacizumab.
- Determine the nature and degree of toxicity of this drug in these patients.
- Determine the progression-free and overall survival of patients treated with this drug.
- Determine the frequency of clinical response in patients treated with this drug.
- Determine the effect of this drug on initial performance status, age, and mucinous or clear cell histology in these patients.
- Correlate biological and imaging markers with 6-month progression-free survival of patients treated with this drug.
Entry Criteria Disease Characteristics:
- Histologically confirmed ovarian epithelial or primary peritoneal
carcinoma
- Recurrent or persistent after initial standard
surgery or chemotherapy
- Incurable with standard surgery, chemotherapy, or radiotherapy
- At least 1 unidimensionally measurable target lesion
- At least 20 mm by conventional
techniques
- At least 10 mm by spiral CT scan
- Outside the area of prior radiotherapy
- Accessible to guided core needle biopsy
- Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin,
cisplatin, or another organoplatinum compound) for primary disease
- May have included high-dose therapy, consolidation,
or extended therapy administered after surgical or non-surgical
assessment
- Patients with only 1 prior platinum-based chemotherapy
regimen must have an initial treatment-free interval of less than 12
months
- Patients with an initial treatment-free interval of
more than 12 months must have progressive disease after prior platinum-based chemotherapy regimen as second-line therapy
- No tumors involving major blood vessels
- No evidence of CNS disease (primary brain tumor or brain
metastases) within the past 5 years
- Ineligible for higher priority GOG protocols (i.e., active phase III GOG protocols for the same patient population)
Prior/Concurrent Therapy:
Biologic therapy: - At least 3 weeks since prior immunologic therapy directed at
malignancy
- No prior bevacizumab
- No other concurrent immunotherapy directed at
malignancy
Chemotherapy: - See Disease Characteristics
- One additional prior cytotoxic regimen for recurrent or persistent
disease allowed
- No prior non-cytotoxic chemotherapy for recurrent or
persistent disease
- No concurrent chemotherapy directed at malignancy
Endocrine therapy: - At least 1 week since prior hormonal therapy directed at
malignancy
- No concurrent hormonal therapy directed at malignancy
- Concurrent hormone replacement therapy allowed
Radiotherapy: - See Disease Characteristics
- Recovered from prior radiotherapy
- No concurrent radiotherapy directed at malignancy
Surgery: - See Disease Characteristics
- At least 28 days since prior major surgery or open biopsy and
recovered
- At least 7 days since prior core biopsy or placement of vascular access
device
- No anticipated need for major surgical procedure during study
participation
Other: - At least 3 weeks since other prior therapy directed at
malignancy
- No prior anticancer therapy that would preclude study entry
Patient Characteristics:
Age: Performance status: - GOG 0-2 (patients who have received 1 prior regimen)
- GOG 0-1 (patients who have received 2 prior
regimens)
Life expectancy: Hematopoietic: - Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- No known bleeding disorder or coagulopathy
- No active bleeding
Hepatic: - Bilirubin ≤ 1.5 times upper limit of normal
(ULN)
- SGOT ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular weight heparin)
- PTT < 1.2 times control
Renal: - Creatinine ≤ 1.5 times ULN
OR - Creatinine clearance > 60 mL/min
- No proteinuria, as indicated by 1 of the following:
- Negative urine dipstick
- Urine protein < 30 mg/dL
- Urine protein < 1,000 mg on 24-hour urine collection
Cardiovascular: - No clinically significant cardiovascular disease, including any of the following:
- Uncontrolled hypertension
- Myocardial infarction within the past 6 months
- Unstable angina within the past 6 months
- New York Heart Association class II-IV congestive heart
failure
- Serious cardiac arrhythmia requiring medication
- Peripheral vascular disease ≥ grade 2
- No stroke within the past 5 years
Other: - No pathologic condition that carries a high risk of bleeding
- No significant traumatic injury within the past 28
days
- No other invasive malignancy within the past 5 years except nonmelanoma
skin cancer
- No uncontrolled seizures within the past 5 years
- No neuropathy (motor and sensory) ≥ grade 2
- No serious non-healing wound, ulcer, or bone
fracture
- No known hypersensitivity to Chinese hamster ovary cell
products or other recombinant human or humanized antibodies
- No active infection requiring parenteral antibiotics
- No known claustrophobia that would preclude MRI
tolerance
- No ferromagnetic implants or pacers
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 3 months after study treatment
Expected Enrollment A total of 55-62 patients will be accrued for this study within 2.2-2.5 years. Outline This is a multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable
toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3
years. Published ResultsHan ES, Burger R, Darcy KM, et al.: Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). [Abstract] J Clin Oncol 26 (Suppl 15): A-5577, 2008. Burger RA, Sill MW, Monk BJ, et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 (33): 5165-71, 2007.[PUBMED Abstract]
Trial Contact Information
Trial Lead Organizations Gynecologic Oncology Group | | | Robert Burger, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase II Evaluation Of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865, IND #7921) In The Treatment of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma | | Trial Start Date | | 2002-04-29 | | Registered in ClinicalTrials.gov | | NCT00022659 | | Date Submitted to PDQ | | 2001-06-28 | | Information Last Verified | | 2004-09-09 | | NCI Grant/Contract Number | | CA27469 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|